{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:29:14Z","timestamp":1785536954625,"version":"3.56.0"},"reference-count":0,"publisher":"American Diabetes Association","issue":"2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1990,2,1]]},"abstract":"<jats:p>During hyperinsulinemic glucose-clamp studies, intravenous infusion of calcitonin gene-related peptide (CGRP) in rats antagonized the ability of insulin to stimulate peripheral glucose disposal by 52% (196 \u00b1 7.2 vs. 105 \u00b1 10.5 \u03bcmol \u00b7 kg\u22121 \u00b7 min\u22121, P &amp;lt; 0.05) and to inhibit hepatic glucose output by 54% (P &amp;lt; 0.01). CGRP also inhibited the in vitro effects of insulin to stimulate hexose uptake in cultured BC3H1 myocytes at all insulin concentrations studied. Amylin is a peptide isolated from amyloid deposits in pancreatic islets of type II (non-insulin-dependent) diabetic subjects, is present in normal \u03b2-cells, and bears a striking homology to CGRP. When synethetic human amylin was infused during clamp studies, it inhibited the ability of insulin to stimulate glucose disposal by 56% (96.9 \u00b1 9.4 vs. 42.4 \u00b1 5.0 \u03bcmol \u00b7 kg\u22121 \u00b7 min\u22121, P &amp;lt; 0.05) and to suppress hepatic glucose output by 64%. Therefore, amylin and CGRP can cause insulin resistance in vivo and may be implicated in insulinresistant states such as type II diabetes mellitus.<\/jats:p>","DOI":"10.2337\/diab.39.2.260","type":"journal-article","created":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T17:22:06Z","timestamp":1379611326000},"page":"260-265","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":118,"title":["Induction of Insulin Resistance In Vivo by Amylin and Calcitonin Gene\u2013Related Peptide"],"prefix":"10.2337","volume":"39","author":[{"given":"Joseph M","family":"Molina","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California\u2008San Diego, La Jolla\u2008Veterans Administration Medical Center\u2008San Diego, California\u2008MRC Immunochemistry Unit and Department of Biochemistry, University of Oxford\u2008Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth J S","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California\u2008San Diego, La Jolla\u2008Veterans Administration Medical Center\u2008San Diego, California\u2008MRC Immunochemistry Unit and Department of Biochemistry, University of Oxford\u2008Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Leighton","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California\u2008San Diego, La Jolla\u2008Veterans Administration Medical Center\u2008San Diego, California\u2008MRC Immunochemistry Unit and Department of Biochemistry, University of Oxford\u2008Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold M","family":"Olefsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California\u2008San Diego, La Jolla\u2008Veterans Administration Medical Center\u2008San Diego, California\u2008MRC Immunochemistry Unit and Department of Biochemistry, University of Oxford\u2008Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/39\/2\/260\/357533\/39-2-260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/39\/2\/260\/357533\/39-2-260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:13:56Z","timestamp":1667405636000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/39\/2\/260\/7408\/Induction-of-Insulin-Resistance-In-Vivo-by-Amylin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,2,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1990,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diab.39.2.260","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,2,1]]}}}